Aridis pharmaceuticals, inc. (ARDS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-28,122

-29,681

-29,472

-29,794

-22,834

-22,105

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

339

338

336

325

315

283

0

0

0

Stock-based compensation expense

2,037

2,010

1,896

1,789

1,605

1,658

0

0

0

Share of loss from equity method investment

0

-

-

0

0

-

-

-

-

Change in fair value of preferred stock warrants

-

-

-

-

-

-1,632

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-

-1,660

0

0

0

-

-

-

-

Other receivables

-1,881

-25

0

0

0

-

-

-

-

Prepaid expenses

245

1,433

2,652

2,480

1,958

2,207

0

0

0

Contract costs

0

-

-

-

-

-

-

-

-

Accounts payable

-727

-469

0

0

0

-

-

-

-

Accrued liabilities

1,424

-2

0

0

0

-

-

-

-

Deferred revenue

-

19,580

9,050

-775

-797

-97

0

0

0

Accounts payable, accrued liabilities and other

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-4,919

-8,159

-20,679

-29,263

-27,648

-24,271

0

0

0

Cash flows from investing activities:
Purchase of property and equipment

0

-

376

108

848

1,000

0

0

0

Net cash used in investing activities

-67

-174

-1,053

-785

-1,525

-1,677

0

0

0

Cash flows from financing activities:
Proceeds from stock option exercises

41

35

0

0

0

-

-

-

-

Net cash provided by financing activities

4,999

4,993

0

0

0

-

-

-

-

Net decrease in cash and cash equivalents

13

-3,340

-16,747

-4,951

-4,076

-859

0

0

0

Supplemental cash flow disclosures:
Cash paid for taxes

2

2

0

0

0

-

-

-

-

Supplemental noncash investing and financing activities:
Preferred stock dividends accrued

-

-

-

-

-

1,357

0

0

0